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SUMMARY 
Patients with acute coronary syndromes (ACS) are treated with dual antiplatelet therapy (DAPT), 
which includes aspirin, an inhibitor of thromboxane A2 (TxA2) production, and an antagonist of the 
P2Y12 receptor for ADP. Based on the recent observation that P2Y12 antagonists also inhibit the 
platelet production of TxA2, it has been suggested that patients with ACS might be safely treated 
with P2Y12 antagonists only. However, the observation that platelets congenitally deficient of P2Y12 
synthesize normal amounts of TxA2 contrasts the results obtained with P2Y12 antagonists. To test 
whether the reported inhibitory effect of  P2Y12 antagonists on TxA2 production  is due to off-target 
effects, or secondary to inhibition of platelet aggregation (PA). Serum TxB2 was measured in 2 
patients with inherited P2Y12 deficiency and 7 healthy subjects in presence/absence of increasing 
concentrations of P2Y12 antagonists added in vitro, and in 20 patients treated with 10 mg/d 
prasugrel (P2Y12 antagonist) or placebo for 14 days in a randomized, double-blind, cross-over 
study. TxB2 levels were also measured after stimulation of citrate-PRP by collagen (0,5µg/mL) or 
arachidonic acid (1mM) in an aggregometer in presence/absence of P2Y12 antagonists, under 
stirring and non-stirring conditions (PA does not occur without stirring). P2Y12 antagonists did not 
decrease serum TxB2 levels both in vitro and ex vivo (prasugrel-treated patients). They partially 
inhibited TxB2 production under stirring, but not under non-stirring conditions.  
In conclusion, P2Y12 antagonists do not inhibit the platelet TxA2 production; therefore, there is no 
pharmacological evidence that aspirin should be withheld in patients with ACS. 
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1. INTRODUCTION 
Patients with acute coronary syndromes (ACS) are treated with dual antiplatelet therapy, which 
includes aspirin, an inhibitor of thromboxane A2 (TxA2) production, and an antagonist of the P2Y12 
receptor for ADP. Based on the recent observation that P2Y12 antagonists also inhibit the platelet 
production of TxA2, it has been suggested that patients with ACS might be safely treated with 
P2Y12 antagonists only. However, the observation that platelets congenitally deficient of P2Y12 
synthesize normal amounts of TxA2 contrasts the results obtained with P2Y12 antagonists.  
The aim of this study will be to better understand the effect of P2Y12 antagonists on platelet TxA2 
production.  
1.1 Platelets 
1.1.1 Platelet biology 
Platelets are small anuclear blood cells, with a discoid shape ranging between 1 to 3 µm in 
diameter. These cell fragments originate from the cytoplasm of megakaryocytes (MKs) in the bone 
marrow and circulate in the human bloodstream for about 10 days. Platelets lack genomic DNA 
1
 
but contain megakaryocyte-derived messenger RNA (mRNA) and the translational machinery 
needed for protein synthesis including ribosomes, and initiation and termination factors 
2
. 
Furthermore, platelets contain three types of secretory organelles known as α-granules, δ-granules 
(dense) and lysosomes, which are generated by the budding of small vesicles containing granule 
cargo from the trans-Golgi zone of the Golgi complex in MKs 
3
. The number of α-granules per 
platelet depends on cell size but and may range between 40 and 80. They contain many proteins, 
such as coagulation factor V, thrombospondin, P-selectin, von Willebrand Factor (vWF) and 
fibrinogen. The δ-granules, compared with α-granules, are smaller, fewer, and have high 
morphological variability. They are rich in ATP and ADP, serotonin, pyrophosphate, calcium, and 
magnesium. Human platelets also contain few lysosomes (no more than 3), which contain at least 
13 acid hydrolases. Other organelles present in the platelet cytoplasm include a small number of 
simple mitochondria involved in energy metabolism, glycosomes 
4
, electron dense chains and 
clusters 
5
, and tubular inclusions 
6
.  
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1.1.2 Platelet in primary hemostasis 
 
The main role of blood platelets is to ensure primary haemostasis, which means the rapid cessation 
of bleeding after tissue trauma and the maintenance of the integrity of the endothelium, in part 
through the release of proangiogenic cytokines and growth factors. The balance between blood 
fluidity and rapid thrombus formation in response to injury is regulated by endothelial cells, which 
synthesize either inhibitors or activators of platelet aggregation and blood clotting 
7,8
. Under normal 
physiological conditions, platelets circulate close to the endothelium without establishing/ forming 
stable adhesion contacts. The anti-adhesive phenotype of vascular endothelium cells towards 
platelet is maintained by at least 4 intrinsic pathways. The arachidonic acid-prostacyclin (PGI2) and 
the L-arginine-nitric oxide (NO) pathways inhibit platelet activation by the stimulation of cAMP 
and cGMP production respectively, whereas endothelial ecto-adenosine diphosphatase (ecto-
ADPase/CD39) is involved in ADP metabolism, which is necessary to prevent premature platelet 
activation at the vessel wall. Furthermore, thrombomodulin rapidly inhibits the prothrombotic effect 
of α thrombin, reducing platelet activation and fibrin generation (Figure 1).  
 
At sites of vascular injury, platelets interact with the damaged vessel, to form a platelet aggregate. 
The initial platelet tethering at the surface and subsequent platelet-platelet cohesion are typically 
differentiated into the following  steps: adhesion, activation, secretion and aggregation of platelets 
9
.  
 
 Platelet Adhesion 
After vascular injury, such as rupture or erosion of the vessel wall, subendothelial matrix 
proteins such as collagen, von Willebrand factor (vWF), fibronectin and laminin become 
exposed to the circulating blood. These proteins support platelet adhesion via the engagement of 
specific receptors, thus rapidly recruiting individual platelets at the site of subendothelial 
damage. The initial tethering of platelets occurs via the interaction between glycoprotein Ib 
(GPIb), a component of GPIb-V-IX platelet complex, and exposed collagen-bound vWF. This 
bond has a rapid dissociation rate and is therefore unable to support stable adhesion, resulting in 
platelet translocation along the vessel wall. Translocating platelets engage with collagen in the 
vessel wall through their adhesion receptors glycoprotein VI (GPVI) and GPIa. GPVI is the 
major collagen receptor, whose stimulation induces the intracellular calcium flux necessary for 
stable platelet adhesion, cytoskeletal reorganization, integrin glycoprotein IIb/IIIa (αIIbβ3) 
activation and the release of soluble agonists.  
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 Platelet Activation and Secretion 
 
After the initial adhesion, platelets undergo the repair process that requires a quick response to 
autocrine and paracrine mediators. Platelets experience a complex series of morphological and 
biochemical changes that lead to the release of platelet granular content such as ADP and serotonin 
(5-HT), as well as to the synthesis of TxA2. These endogenous agonists act to enhance platelet 
activation by interacting with specific G-protein coupled receptors expressed on the platelet 
membrane. Briefly, ADP and 5-HT are released from platelet dense granules and bind their specific 
receptors. Activation of the 5-HT2A receptor by 5-HT and the P2Y1 receptor by ADP (both coupled 
to a Gq protein) induces an increase in intracellular Ca
2+
 levels, whereas activation of P2Y12 (couple 
to Gi protein) by ADP activates PI3kinase and inhibits adenylate cyclase. TxA2 is synthesized in 
activated platelets starting from arachidonic acid (AA) by cyclooxygenase (COX). Once formed, 
TxA2 diffuses across the platelet membrane and activates other platelets through the interaction 
with two surface membrane TxA2 receptors, TPα and TPβ, coupled to the proteins Gq and G12 or 
G13, which activate phospholipase C (PLC). This enzyme degrades membrane phospholipids, thus 
releasing secondary messengers inositol triphosphate (IP3) and diacylglycerol (DAG). DAG 
activates intracellular protein kinase C (PKC), which causes protein phosphorylation, whereas IP3 
increases cytosolic Ca
2+
 levels from the endoplasmic reticulum. In addition platelets provide a 
catalytic surface necessary for local production of thrombin thus enhancing platelet activation. 
Indeed, at the site of injury prothrombin is proteolytically cleaved to form thrombin, a serine 
protease that converts soluble fibrinogen into insoluble strands of  fibrin. Subsequently, thrombin 
mediates cleavage of the N-terminal extradomain of protease-activated receptors (PAR)-1 and 
(PAR)-4, that increases intracellular calcium (Ca
2+
). The generation of thrombin is contingent upon 
the expression of tissue factor (TF) on the surface of fibroblasts, smooth muscle cells, endothelial 
cells and leukocytes. Thrombin is among the most potent stimulators of platelets. 
 
 Platelet Aggregation 
 
Aggregation is the amplification step that involves accumulation of platelets into the hemostatic 
thrombus through release of soluble agonists that enhance recruitment of further platelets. The 
stimulation of Gq and Gi signaling pathways leads to activation of the glycoprotein complex 
GPIIb/IIIa. Activated GPIIb/IIIa binds multiple ligands, including vWF 
10
 
11
, fibrinogen 
12
, fibrin 
and fibronectin 
13
, able to form stable platelet aggregates 
14
. The primary hemostatic plug is 
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consolidated by fibrin generation at the site of injury. Platelet activation is under tight negative 
control to limit and contain thrombus formation within the boundaries of the lesion in the vessel 
wall. 
 
1.1.3 Role of platelets in arterial thrombosis and atherosclerosis 
Arterial thrombosis and atherosclerosis have been considered separate entities with different 
pathogenic mechanisms, natural histories and therapies. Arterial thrombosis is primarily mediated 
by platelets and fibrin 
15
, whereas pathogenesis of atherosclerosis is multifactorial but is mainly 
promoted by altered function of endothelial and smooth muscle cells, deposition of lipids 
metabolized abnormally and oxidized in the vascular wall, and the local infiltration of leukocytes 
16
 
17
. However, it is becoming clear that the cellular and biochemical interactions underlying 
thrombosis are also directly relevant to atherosclerosis 
18
 . 
 
Arterial thrombosis 
Arterial thrombosis is an acute complication that occurs after rupturing or erosion of unstable 
atherosclerotic plaque in the blood vessels. In the case of coronary heart disease it causes heart 
attack, whereas in the case of cerebrovascular disease it leads to stroke. The most abundant 
components of the occlusive arterial thrombi formed   are platelets with fibrin. On the other hand, 
platelets seem to be less relevant in the pathogenesis of venous thromboembolism.  
Platelet thrombus formation is thought to occur in successive stages. After vascular injury, under 
conditions of rapid blood flow that occur in stenotic diseased arteries, platelets adhere to the 
exposed subendothelium (platelet adhesion), are activated (platelet activation) and secrete their 
granule contents (platelet secretion), including some platelet agonists (ADP and serotonin) which 
contribute to the recruitment of additional platelets to form aggregates (platelet aggregation) by 
interacting with specific platelet receptors. In this pathological condition the mechanism supporting 
platelet adhesion and aggregation at the site of vascular injury follows the physiological processes 
previously described in the paragraph 1.1.2. 
 
Atherosclerosis 
Atherosclerosis is in part an inflammatory disease, affecting medium and large size arteries through 
the accumulation of fatty substances, cholesterol, cellular waste product, calcium and fibrin within 
the arterial intima resulting in atherosclerotic plaques. Atherosclerosis starts when these deposits 
(plaque) lead to the inner surface of the blood vessel becoming damaged and the narrowing of the 
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lumen, making it harder for blood to flow through. Plaques may induce partial or total obstruction 
of blood flow through the artery (stenosis) and in the case that a piece of the plaque breaks off, 
trigger the formation of a blood clot (thrombus), causing heart attack or stroke. 
Several factors promote the process of atherosclerosis, they are known as risk factors and include 
19
: 
 Cigarette smoke 
 Decreased physical activity 
 Consumption of unhealthful foods (rich in salt, fat and calories) 
 Harmful use of alcohol 
 High blood pressure (hypertension) 
 Diabetes 
 High levels of cholesterol and triglycerides 
 Overweight and obesity 
 Male gender 
 Genetic disposition 
 Psychological factors (e.g. stress, depression) 
 Other risk factors (e.g. excess homocysteine) 
 
Platelets play a central role in arterial thrombosis  but  may also participate in the development and 
progression of atherosclerotic plaque. Platelets promote the progression of plaque formation by 
forming platelet/leukocyte aggregates and via adhesion to the endothelium. Specific pro-
inflammatory signals make endothelial cells more adhesive toward platelets, stimulating the 
production of various platelet-derived inflammatory molecules that provide a positive feedback 
loop for the activation of further endothelial cells. Indeed, under inflammatory conditions platelets 
can adhere to the intact but activated endothelial cells. 
20
 
21
 
22
. Additionally an increase of 
circulating activated platelets promotes atherosclerosis. Endothelial-bound platelets are highly 
effective at recruiting leukocytes from flowing blood and also enhance leukocyte adhesion and 
transmigration to the site of the proinflammatory stimulus.  
Activated-platelets induce shorter plaque formation by releasing and exposing P-selectin on plasma 
membrane, which binds to the P-selectin glycoprotein ligand 1 (PSGL-1) receptor on monocyte cell 
surface, thus forming platelet-monocyte aggregates. Once activated, platelets are capable of time-
dependent synthesis of protein mediators, such as interleukin-1β, which cause an increase in the 
release of chemokines and up-regulate molecules that promote adhesion of neutrophils and 
monocytes to the endothelium 
23
. Another important mediator released from platelets is the CD40 
ligand which triggers an inflammatory response of the endothelial cells 
24
. This ligand is stored in α-
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granules of resting platelets and becomes rapidly exposed on cell surface following platelet 
activation 
25
. CD40 ligand undergoes cleavage over a period of minutes to hours, generating a 
functional soluble fragment. The soluble CD40 ligand is released into the extracellular environment 
inducing endothelial cells to produce reactive oxygen species, 
26
 adhesion molecules, chemokines 
24
, and tissue factor 
27
 leading to an inflammatory response. The interaction between platelets, 
endothelial cells and leukocytes thus establishes a localised inflammatory response that can 
accelerate the early formation of atherosclerosis lesions. In addition platelets release platelet-
derived growth factor (PDGF), which stimulates smooth muscle proliferation and angiogenesis in 
the plaque 
28
. 
 
 
 
 
Figure 1. Picture modified from 
29
 The antiadhesive phenotype of endothelial cells is maintained through four intrinsic 
pathways: ecto-ADPase, prostaglandin I2 (PGI2), nitric oxide (NO) and the thrombomodulin (TM)-activated protein C 
(APC) pathways. 
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1.2 Cardiovascular disease  
Cardiovascular disease (CVD) refers to a class of diseases that affect the cardiovascular system, 
which involves the heart, brain and blood vessels (arteries and vein). According to the World Health 
Organization classification 2008, CVD, caused mostly by atherosclerosis and/or hypertension, is the 
major cause of morbidity and mortality worldwide. This is confirmed by the Framingham Heart 
Study, which found that atherothrombosis significantly reduces life expectancy.  
CVD of coronary arteries, known as coronary artery disease (CAD) is associated with chronic 
stenosis and is characterized by unchanged or slowly progressing symptoms over time.  
When the CAD condition is documented, patients are treated with daily dose of aspirin in order to 
prevent potential adverse cardiovascular events, in fact in these patients there is a relevant net-
clinical benefit of long-term administration of aspirin. 
30
 (table 1) 
Stable CAD become unstable when dynamic stenosis or occlusion occur due to plaque rupture, with 
subsequent exposure of subendothelial vessel structures to blood flow, leading to thrombus 
formation in the artery. The ruptured atherosclerotic plaque, fissure, erosion, or their combination, 
may lead to lack of oxygen with a perfusion imbalance that lead to a myocardial ischemia. 
Prolonged ischemia can lead to myocardial infarction 
31
. This spectrum of clinical conditions is 
referred to as acute coronary syndrome and is classified on the basis of the electrocardiogram 
(ECG) test: 
1. ST-segment elevation myocardial infarction (STEMI);  
2. non-ST-segment elevation ACS (NSTE-ACS), which may be divided, on the basis of 
cardiac troponin measurements, into:  
- non-ST-segment elevation myocardial infarction (NSTEMI), if there is an increased 
value for troponin; 
- ustable angina. 
These criteria for diagnosis reflect the pathophysiological conditions: NSTE-ACS occurs when the 
thrombus is not completely occlusive or is so only transiently, while STEMI is caused by the intra-
coronary thrombus completely occluding the vessel. The management of patients with ischemic 
coronary disease consists of 2 approaches: revascularization (percutaneous coronary intervention 
(PCI) or coronary artery bypass graft (CABG)) and systemic theray (aspirin, P2Y12 antagonists, 
lipid-lowering therapy, angiotensin-converting enzyme inhibitors, and β-blockers) ( table 1). 
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Table 1. Table modified from 
32
. Guidelines for Antithrombotic Therapy in the prevention and 
treatment of thrombosis among patients with CAD (according to European Society of Cardiology, 
ESC
33
 
34
)  
Treatment Preclinical 
CAD 
Stable  
CAD 
Elective 
PCI 
NSTE-ACS STEMI 
Aspirin II-A I-A I-A I-A I-A 
Clopidogrel - I-A I-A I-Ba I-C 
Prasugrel - - - 
IIa-B 
I-B
b
 
I-B 
Ticagrelor - - - I-B I-B 
GPIIb-IIIa 
antagonists 
- - 
IIa-C 
(bailout 
situation 
only) 
I-B only in high 
risk PCI
c 
 
Not for routine 
use (IIIa) 
IIa-A
d
 IIa-B
e
 
IIb-B
f  
No benefit of 
upstream 
therapy (III-B) 
 
a 
Only if prasugrel or ticagrelor are not an option 
b 
In case of known coronary anatomy, intent to PCI and no pretreatment with P2Y12-inhibitors 
c 
At the time of PCI 
d 
Abciximab 
e 
Eptifibatide 
f 
Tirofiban 
Classes of recommendation: 
Class I: Benefits >>> Risk: Procedure /treatment should be performed/administered. 
Class IIa: Benefits >> Risk: Additional studies with focused objective needed; it is reasonable to perform 
procedure/administer treatment. 
Class IIb: Benefits ≥  Risk: Additional studies with broad objective needed; additional registry data would be helpful; 
procedure/treatment may be considered. 
Class III: Risk > Benefits: Procedure /treatment should not be performed/administered since it is not helpful and may be 
harmful. 
Levels of evidence: 
Level A: Multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analysis 
Level B: Limited populations evaluated; data derived from a single randomized trial or nonrandomized studies 
Level C: Very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care.  
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1.3 Pharmacological treatment of CAD: antiplatelet drugs 
 
ADP and TxA2 are released when platelets adhere to the vessel wall and therefore act as mediators, 
with an autocrine and paracrine positive feedback loop, that amplify platelet response to 
stimulation. Both ADP and TxA2 act selectively on single pathways of platelet aggregation. The 
discovery of the importance of platelets in cardiovascular disease led to the common use of aspirin 
and P2Y12 receptor antagonists in clinical practice.  
1.3.1 Aspirin  
1.3.1.1 Thromboxane A2 pathway  
 
TxA2 belongs to the family of eicosanoids, which includes prostaglandins, prostacyclin, 
leukotrienes, and epoxygenases. In humans eicosanoids derive from arachidonic acid, a 20-carbon 
fatty acid containing four double bonds, which is liberated from membrane phospholipids following 
an intracellular increase in calcium and the action of phospholipase A2 or C. 
35
 Once liberated 
arachidonic acid is converted by COX-1 in two independent enzymatic reaction steps, producing 
first prostaglandin (PG) G2, via a cyclooxygenase function, and subsequently  to PGH2, via a 
peroxidase function. PGH2 is the substrate for several synthases that generate a range of bioactive 
prostanoids such as PGD2, PGE2, PGI2 and TxA2. While almost all human tissue is capable of 
generating PGH2, its metabolite is tissue-specific and depends on the presence of tissue-specific 
enzyme. In platelets, thromboxane synthase (TXS) is responsible for the conversion of PGH2 into 
TxA2, a known strong platelet agonist (Figure 2). Once produced, TxA2 has a short half-life (30 
seconds) and acts on neighboring cells via autocrine or paracrine systems. TxA2 undergoes rapid 
non-enzymatic hydrolysis to the inactive TxB2 
36
, further metabolized to 2,3-dinor-TxB2 and 11-
dehydro-TxB2, eventually excreted in urine. Endothelial cells, on the other hand, contain PGI2 
synthase, which produces prostacyclin. 
35
 There are three isoforms of the COX enzyme. COX-1 is 
constitutively expressed mostly in platelets. While the gene for COX-2 is present in nucleated cells, 
it is only expressed when induced in presence of inflammatory stimuli 
37
. COX-3 is the third 
isoform which derives from the same gene as COX-1; in humans COX-3 mRNA is most abundant 
in the cerebral cortex and heart 
38
. 
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Figure 2. Modified from 
39
 Thromboxane pathway:  PLA2, phospholipase A2; COX-1, cyclooxygenase-1; COX-2, 
cyclooxygenase-2; TXS, thromboxane synthase; PGH2, prostaglandin H2; TxA2, thromboxane A2; TXB2, 
thromboxane B2;  
 
Thromboxane A2  receptor 
 
TxA2 exerts its action through the specific G protein-coupled TxA2 receptor (TP). The TP receptor 
is a member of the G-protein-coupled receptor superfamily, which in turn regulates several 
effectors, including phospholipase C, guanine nucleotide exchange factor of the small G protein 
Rho (RhoGEF) and adenylyl cyclase. TP is expressed in various tissues such as platelets, 
endothelial cells, smooth muscle cells, monocytes, macrophages, kidney, heart and spleen cells. 
40
 
In human platelets two TP isoforms have been described, TPα and TPβ, which occur by alternative 
splicing of their common mRNA. 
41
 
42
 Although mRNA for both isoforms have been isolated from 
platelets 
43
, TPα seems to be the predominant isoform expressed on the platelet surface 44. The wide 
distribution of TP suggests that TxA2 is involved in a wide range of physiological and 
pathophysiological conditions. Genetic variations affecting TP receptors are associated  with a mild 
bleeding phenotype. To date, two quantitative defects causing reduced TP receptor expression have 
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been identified, (c167dupG) 
45
 and (W29C) 
46
 as well as one qualitative defect caused by a point 
mutation (R60L) 
47
 in the first cytoplasmic loop of TP. Another mutation (D304N) 
48
 associated 
with reduced ligand binding to TP, has been described . TP defects may be suspected in patients 
with defective response to the TxA2 analog U46619, arachidonic acid, and collagen.  
 
1.3.1.3  Aspirin Pharmacology 
 
Aspirin exerts its cardioprotective effect by targeting one of the major activators of platelet TxA2 
synthesis, so consequently treatment with aspirin is fundamental to the management of patients  
with cardiovascular disease at different levels (Table 1). 
Aspirin irreversibly inhibits COX-1 
49
 
50
 by acetylating Ser529 residue. Aspirin inhibits not only 
TxA2 production by COX-1 but also the synthesis of other prostanoids via inhibition of COX2. 
Aspirin is rapidly absorbed in the stomach and upper small intestine, primarily by passive diffusion 
of non-dissociated acetylsalicylic acid (ASA) across gastrointestinal membranes. Generally, peak 
plasma level occurs 30 to 40 minutes after the ingestion of aspirin and the reduction of TxA2 is 
evident after 1 hour. However, other formulations of ASA, such as the enteric-coated form, takes up 
to 3-4 hours to reach peak plasma levels. Aspirin is an effective anti-thrombotic agent when used 
long term at doses between 50 and 100 mg/day 
51
 
52
. In contrast, randomized trials have shown no 
evidence for increase of efficacy of aspirin (>300mg/day) as antithrombotic agent at higher doses, 
there is however a dose-dependent effect on gastroenterological complications 
51
 
52
 
53
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1.3.2  ADP/ P2Y12 antagonists 
 
1.3.2.1  ADP pathway  
 
Adenosine diphosphate (ADP), the first known low molecular weight platelet aggregating agent, 
plays an important role in platelet function despite being a weak platelet agonist. As such, it only 
induces platelet shape change and reversible aggregation in humans. Platelet secretion and 
secondary aggregation  observed after stimulation with ADP of normal, human citrated platelet-rich 
plasma are due to the aggregation-dependent formation of TxA2. ADP is released in high 
concentration from platelet dense granules where it is stored and amplifies platelet responses 
induced by other agonists  
54
 
55
 and stabilizes platelet aggregate 
56
 
57
. ADP stimulates two specific G 
protein coupled P2 receptors on the platelet surface. The transduction of its signal involves both a 
transient rise in free cytoplasmic calcium, mediated by the Gq-linked P2Y1 receptor, and inhibition 
of adenylyl cyclase, which is mediated by the Gi-linked P2Y12 receptor 
58
. The activation of  P2Y1 
receptor by ADP mediates platelet shape change and initiates platelet aggregation, whereas P2Y12 
amplifies the platelet aggregation response. 
59
 Concomitant activation of both G protein-coupled 
receptors is essential to elicit normal platelet aggregation 
60
 
58
 (Figure 3) 
 
P2Y12 receptor 
The P2 receptors, which interact with purine and pyrimidine nucleotides, are divided into two 
groups: G protein-linked or metabotropic, termed P2Y, and ligand-gated ion channels or ionotropic, 
termed P2X 
61
. The P2Y receptors are seven-membrane-spanning proteins with a molecular mass of 
41 to 53 kD after glycolysation 
61
. The carboxyl terminal domain is on the cytoplasmatic side, 
whereas the amino terminal domain is exposed to extracellular environment. The mechanisms of 
signal transduction are shared by most seven-membrane-spanning receptors, and include activation 
of phospholipase C and regulation of adenylyl cyclase activity. The Gq coupled receptor P2Y1 
leads to activation of β-isoforms of phospholipase C (PLC) and  triggers the mobilization of Ca2+ 
into the cytoplasm. The Gi coupled receptor P2Y12 leads to inhibition of adenyl cyclase (AC) with 
an increase of platelet cyclic adenosine monophosphate (cAMP). Co-interaction of the P2Y1 and 
P2Y12 is necessary for normal ADP-induced platelet aggregation, in fact separate inhibition of 
either of them with selective antagonists results in a dramatic decrease in aggregation 
62
 
63
 
60
. The 
stimulation of the ADP receptors, predominately the P2Y12 receptor, assists to activation of integrin 
GP IIb/IIIa (fibrinogen receptor) 
64
 
65
. P2Y12 is important for both normal hemostasis and 
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pathologic thrombosis result this receptor is relevant target for antiplatelet drug and research is very 
interested in this field. 
 
Congenital defect of P2Y12receptor 
Patients with defects of the platelet P2Y12 receptors have been described. Congenital P2Y12 
deficiency is an autosomal recessive disorder, characterized by life-long history of excessive 
bleeding, prolonged bleeding time, abnormalities of platelet aggregation similar to those observed 
in patients with defects of platelet secretion (reversible aggregation in response to weak agonists 
and impaired aggregation in response to low concentrations of collagen or thrombin), except that 
the aggregation response to ADP was severely impaired.  
The diagnosis of P2Y12 defects should be suspected when ADP, even at high concentrations (>10 
µM), fails to induce full and irreversible platelet aggregation, but induces normal platelet shape 
change and borderline-normal mobilization of cytoplasmatic Ca
2+ 
induced by ADP. Furthermore, 
platelets show no inhibition by ADP of prostaglandin E1-stimulated platelet adenylyl cyclase, but 
normal inhibition by epinephrine. In addition, the presence of approximately 30% of the normal 
number of binding sites for [33P]2MeSADP on fresh platelets or [3H]ADP on formalin-fixed 
platelets (which are associated with the ADP receptor P2Y1). 
 
 
 
Figure 3. Figure modified from 
32
. Role of P2Y12 in platelet aggregation. ADP interact with P2Y12, a seven-
transmembrane receptor that is coupled to Gi protein. This bond induces platelet aggregation and amplifies the 
aggregation response that is induced by other agonists or by ADP itself, by interacting with its other platelet receptor, 
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P2Y1. P2Y12 stabilizes platelet aggregates and amplifies the secretion of platelet dense granules stimulated by 
secretion-inducing agonists (coupled to Gq). P2Y12 is coupled to inhibition of adenylyl cyclase (AC) through Gi, this 
function does not appear to be directly related to P2Y12 -mediated platelet activation. However, it could have important 
implications in vivo, where platelets are exposed to the inhibitory prostaglandin PGI2 (prostacyclin), which inhibits 
platelet aggregation by increasing platelet cyclic adenosine monophosphate (cAMP) through activation of AC mediated 
by Gs: inhibition of AC by P2Y12counteracts the inhibitory effect of prostacyclin, thereby favoring the formation of 
platelet aggregates in vivo. 
 
1.3.3.2 P2Y12 antagonists pharmacology 
Thienopyridines (such as ticlopidine, clopidogrel and prasugrel) irreversibly inhibit P2Y12, while 
ticagrelor and cangrelor are reversibly-binding inhibitors. 
66
 
67
 
 
Clopidogrel 
Pharmacology 
 
Molecular mass: 321.82 g/mol 
Figure 4. Chemical structure of clopidogrel 
Ticlopidine and Clopidogrel are structurally related compounds, but ticlopidine has been almost 
completely replaced by clopidogrel in clinical practice, due to the its citotoxicity (neutropenia, 
thrombotic thrombocytopenic purpura) 
32
. In fact, clopidogrel resulted a better tolerated and safer 
drug than ticlopidine. Clopidogrel is absorbed as a pro-drug in the intestine and then modified via 
two competing pathways in the liver. In one, clopidogrel is rapidly metabolized by human 
carboxylesterase 1 (hCE1) to an inactive acid metabolite 
68
, about 75% of clopidogrel administrated 
is converted through this step 
69
. In the second pathway, clopidogrel is metabolized in a two-step 
process, first to 2-oxo-clopidogrel by CYP2C19, CYP1A2 and CYP2B6, subsequently into the 
active metabolite by CYP2B6, CYP3A2, CYP2C9 and CYP2C19 and in inactive acid metabolite of 
2-Oxo-Clopidogrel by esterase 
68
. The active metabolite irreversible binds to P2Y12 by forming a 
covalent disulfide bond with cysteine residues. The consequence of an irreversible inhibition is that 
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stays on for entire life span of a circulating platelets 
70
. Gastrointestinal side effects are also 
described during treatment with clopidogrel, even if clinically less severe than in aspirin-treated 
patients 
71
. 
Despite its proven antithrombotic efficacy clopidogrel has some important limitations: 
1. The need for metabolism to active metabolite causes a delayed antiplatelet effect, with a 
maximum plateau of inhibition of ADP-induced platelet aggregation from 4 to 5 days after 
daily dose of 75 mg of clopidogrel. However, the delayed of action of clopidogrel can be 
reduced to approximately 2-5 hours by a loading dose of 300-600 mg 
72
 
73
.  
2. There is interindividual variability in the response to clopidogrel, which is due mostly to 
interindividual differences in the extent of metabolism of the prodrug in the liver (mutation 
of CYP2C19 and other CYP isoform) 
74
 
75
 
32
. Furthermore, the variables that can affect the 
pharmacodynamics response to clopidogrel are several as lack of compliance, reduced 
absorption, interaction with other drugs, age, high body mass index, diabetes mellitus, renal 
insufficiency in diabetes mellitus, pre-existed variability in platelet response to ADP, 
increased platelet turnover, tobacco smoking.  
 
Clinical Trials 
Long-term administration of clopidogrel was associated with a modest but statistically significant 
advantage over aspirin in reducing adverse cardiovascular outcomes in patients with established 
cardiovascular disease in the CAPRIE trial. In other large well designed multicenter trials the 
addition of clopidogrel to aspirin therapy improved outcomes in patients with acute coronary 
syndromes (Table 2). Results of several large randomized trial, therefore, have established 
clopidogrel as an effective and well tolerated antiplatelet agent for the secondary prevention of 
ischaemic events in patients with various cardiovascular conditions, including those with ischaemic 
stroke or acute coronary syndromes. In addition, treatment guidelines from the US and Europe 
acknowledge the importance of clopidogrel in contemporary cardiovascular medicine.  
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Table 2. Clinical Trial of Clopidogrel 
Trial Treatment N Patients Primary endpoint Follow-up 
Primary endpoint data 
(%) 
Safety 
(%) 
REF. 
 
Clopidogrel vs ASA 
CAPRIE 
 
CLO 75 mg/d vs ASA 325 mg/d 19.185 Previous AMI, 
Ischemic stroke, 
or PAD 
Composite of outcome of 
ischemic stroke, MI o 
vascular death 
1.9 years 5.3 vs 5.8 (p=0.043) No difference 71 
Clopidogrel + ASA vs ASA 
CHARISMA CLO 75 mg/d plus low dose ASA 75-162 mg/d vs PL 
plus low dose ASA  
15.603 CVD or multiple 
risk factor 
Composite of MI, stroke or 
death from CV causes 
28 months 6.8 vs 7.3 (p=0.22) Severe bleeding  
1.7 vs 1.3 (p=0.09) 
Moderate  bleeding 
 2.1 vs 1.3 (p<0.001) 
76 
77 
 
Clopidogrel + ASA vs ASA 
CURE CLO 300 mg  LD, then 75 mg/d plus ASA 75-325 
mg/d vs ASA  
12.562 NSTE ACS, 
unstable angina 
Composite of death from  CV 
causes, nonfatal MI  and 
stroke  
3-12 months 9.3 vs 11.4 (p<0.001) Major bleeding  
3.7 vs 2.7 (p=0.001) 
78 
COMMIT CLO 75 mg/d plus ASA 162 mg/d vs PL plus ASA 45.852 STEMI Composite of CV death, re-
infarction, or stroke 
28 days 9.2 vs 10.1 (p=0.002) Fatal bleeding 
0.32 vs 0.32 (p=0.92) 
79 
CREDO CLO 300 mg LD plus ASA 325 mg or PL 3-24 h 
before PCI, then CLO 75 mg/d plus ASA 325 mg/d 
throught day 28 then CLO 75mg/d in the LD group or 
PL  
2.116 CAD undergoing 
PCI 
28 days: Composite of death, 
MI or urgent TVR 
1 year: Composite of death, 
MI or stroke 
 
1 year 28 d: 6.8 vs 8.3 (p=0.23) 
1 y:  8.5 vs 11.5 
(p=0.02) 
Major bleeding  
8.8 vs 6.7 (p=0.07) 
80 
 
(Double-dose Clopidogrel vs standard dose of Clopidogrel )+ (high dose ASA vs low dose ASA) 
 
CURRENT-OASIS 
7 
CLO 300 mg LD then 75 mg/d, or 600 mg LD then 
150 mg/d on days 2-7, then 75 mg/d on day 8-30 plus 
ASA ≥ 300 mg LD then 75-100 mg/d or 300 mg/d  
25.086 ACS undergoing 
PCI 
Composite of CV death, MI 
or stroke 
30 days 4.2 vs 4.4 (p=0.3) Major bleeding  
2.5 vs 2.0 (p=0.01) 
81 
 
Clopidogrel + ASA vs ASA 
CLARITY- TIMI 28 CLO 300 mg LD then 75 mg/d plus ASA 150-325 
mg LD then 75-162 mg/d vs ASA 
3.491 Acute STEMI, 
received a 
fibrinolytic agent 
Composite of occluded infart 
related artery on angiography, 
death or MI before 
angiografy 
30 days 15.0 vs 21.7 (p<0.001) Major bleeding  
1.9 vs 1.7 (p=0.8) 
82 
CLO= Clopidogrel; ASA= Aspirin; AMI= acute myocardial infarction MI= myocardial infarction; PAD= peripheral artery disease; PL= placebo; CAD= cardiovascular disease; CV= cardiovascular; 
LD= loading dose; ACS= Acute coronary syndrome; STEMI= ST-segment elevation MI; NSTE= non-ST-segment elevation MI; PCI=percutaneous coronary interventio
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 Prasugrel 
Pharmacology 
OH
O
O
F
SH
N
 
2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetra-hydrothieno[3,2-c]pyridine; 
Molecular mass: 349.42; 
 
Figure 5. Chemical structure of prasugrel and the metabolic pathway of prasugrel leading to its active metabolite 
83
 
 
Prasugrel is a thienopyridyl pro-drug that is rapidly metabolized to its active metabolite R-138727 
(Figure 5 ) and irreversibly inhibits platelet P2Y12 receptors. Oral administration of prasugrel is 10 
and 100 times more effective on an equal-dose on inhibition of platelet aggregation than clopidogrel 
and ticlopidine, respectively 
84
, although the active metabolites for prasugrel and clopidogrel have 
equipotency at the P2Y12 receptor in vitro 
85
. In addition, prasugrel has a more rapid onset of action 
than clopidogrel and is less dependent to CYP enzyme than clopidogrel, as has a distinct chemical 
structure that allow a more efficient conversion to its active metabolite. The biotrasformation of 
prasugrel to its active metabolite, 2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-
3-piperidinylidene] acetic acid, requires ester bond hydrolysis by carboxylesterase (hCE)-2 in the 
intestine 
86
 
83
 forming the thiolactone, and then an oxidation by intestinal and epatic cytochrome 
P450–mediated, mainly CYP3A and CYP2B6 87, with smaller contributions by CYP2C9 and 
CYP2C19 
87
.  
The different pharmacokinetics and pharmacodynamics of prasugrel compared with clopidogrel can 
be summarized as follows 
88
:  
1. fast appearance of its active metabolite in circulating blood within 15 minutes of dosing, 
which reaches maximal plasma concentration at ≈30 minutes;  
2. higher mean area under the concentration-time curve of the active metabolite of prasugrel 60 
mg than that of clopidogrel 600 mg;  
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3. faster and greater mean inhibition of P2Y12-dependent platelet function after a 60-mg 
loading dose and 10-mg maintenance dose than after a 300- or 600-mg loading dose and 75- 
or 150-mg maintenance dose of clopidogrel;  
4. no influence of the CYP genotype on its pharmacokinetics and pharmacodynamics;  
5. much lower interindividual variability in the inhibition of P2Y12-dependent platelet 
responses and extremely low prevalence of subjects who display resistance to prasugrel. 
 
Clinical trials 
The more favorable pharmacokinetics and pharmacodynamics of prasugrel compared to clopidogrel 
result in greater clinical benefit as showed by data of the phase III TRITON TIMI-38 trial, in which 
patients were randomized to receive prasugrel 60 mg loading dose followed by 10 mg/ day or 
clopidogrel 300 mg loading dose followed by 75 mg / day for 6-15 months. The study was a 
randomized, double-blind, parallel group, multinational trial, which evaluated 13,608 high risk 
patients with ACS who require PCI 
89
. Prasugrel was associated with fewer ischemic events but 
higher incidence of bleeding complications. 
 
Ticagrelor 
Pharmacology 
 
 
(1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino}-5-(propylthio)- 
3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol. 
Molecular mass = 522.57; 
Figure 6. Chemical structure of ticagrelor.  
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Ticagrelor (previously known as AZD6140) belongs to a new chemical class of compounds, the 
cyclopentyl-triazolo-pyrimidines, which target the P2Y12 receptor (figure 6) 
90,91
. It is the first 
reversibly binding oral P2Y12 receptor antagonist with a pIC50 value of 7.9 for inhibition of 30 µM 
ADP-induced aggregation of human-washed platelets and no significant affinity for other P2 
receptor at concentrations >3 µM 
90
.  
In contrast to the other antiplatelet drugs, ticagrelor appears to inhibit P2Y12 receptor in a 
noncompetitive manner suggesting the existence of an independent receptor binding site, making it 
an antagonist 
67
. The drug does not need activation whereby the pharmacological effect of ticagrelor 
is not influenced by CYP genotypes. It gives a more complete and consistent platelet inhibition 
compared to clopidogrel 
92
. Ticagrelor has a rapid beginning of action, reaching maximal inhibition 
of platelet function in about 2 hours 
93
 
94
. Although the plasma half-life of ticagrelor is 6-8 hours 
93
 
95
, the duration of its inhibitory effect is much longer, because platelet function returns to near 
normal levels after about 5 days following cessation of treatment 
96
. Ticagrelor has been shown to 
inhibit erythrocyte adenosine uptake likely via the equilibrative nucleoside transporter 1 (ENT1) 
97
 
and to augment adenosine-induced coronary blood flow, possibly contributing to reduced 
myocardial infarction size 
98
.  
Briefly, ticagrelor has the potential to address many of the limitations of thienopyridine therapy:  
 
1. is not a prodrug and therefore does not require metabolic activation, has a rapid and 
reversible concentration dependent inhibitory effect on the P2Y12 receptor;  
2. provides greater and more consistent inhibition of ADP-induced platelet aggregation than 
clopidogrel; 
3. offers the potential for greater flexibility in the management of patients at risk for 
thrombotic events due to rapid onset and offset of antiplatelet effect;  
 
Clinical trials 
 
The clinical relevance of ticagrelor was evaluate in the phase III clinical trial PLATO, in which 
ticagrelor (180 mg loading dose, 90 mg bid maintenance dose) was compared to clopidogrel (300-
600 mg loading dose, 75 mg daily maintenance dose) for the prevention of major adverse cardiac 
events (MACE) among patients with non-ST or ST elevation acute coronary syndrome (ACS). The 
main results showed that ticagrelor reduced the rate of a composite of death from vascular causes, 
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myocardial infarction (MI), or stroke (9.8% versus 11.7%)
99
. The incidence of bleeding 
complications was higher in ticagrelor-treated patients, compared to clopidogrel-treated patients. 
 
1.4 Role of P2Y12 in thromboxane A2 production  
Recent studies showed that inhibition of P2Y12 is associated with markedly decreased platelet 
production of TxA2 
100
 
101
 
102
 
103
. Based on these findings, it has been suggested that patients with 
ACS might be safely treated with P2Y12 antagonists only. However, the observation that platelets 
congenitally deficient of P2Y12 synthesize normal amounts of TxA2 contrasts the results obtained 
with P2Y12 antagonists. Therefore, the role of P2Y12 in stimulation of the platelet production of 
TxA2 is still unclear. 
 
 
 
  
  
 
25 
 
2.  AIMS OF THE STUDY 
The aim of this study was to evaluate the effect of P2Y12 antagonists on platelet TxA2 
production. 
In particular, specific objectives of the study were: 
1. to evaluate whether or not P2Y12 inhibitors have off-target effects that affect TxA2 
platelet production.  
2. to evaluate whether or not the reduction of TxB2 production due to P2Y12 inhibitors 
recently reported by some authors is secondary to the inhibition of platelet 
aggregation. 
3. to assess whether inhibition of P2Y12 synergizes with aspirin in inhibiting the platelet 
production of TxA2. 
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3. DESIGN OF THE STUDY  
1. Serum TxB2 levels were measured in patients treated with 10 mg prasugrel q.i.d. or placebo 
for 14 days (double blind, randomized study).  
Serum TxB2 levels were measured after in vitro addition of P2Y12 inhibitors at high 
concentration to blood samples from: 
 healthy subjects  
 patients with severe inherited P2Y12 defects  
2. TxB2 levels were measured in the supernatant platelet-poor plasma after stimulation of 
platelet-rich plasma (PRP) with platelet agonists in: 
 healthy subjects  
 patients with severe inherited P2Y12 defects 
  under the following experimental conditions: 
 By stirring the samples of PRP at a constant speed: constant stirring of PRP 
samples is essential to allow platelet aggregation to occur 
 Under no-stirring conditions, which prevent the formation of detectable platelet 
aggregates  
3. A. Platelet aggregation and TxB2 production after stimulation of PRP with platelet 
agonist in the presence of aspirin and cangrelor, alone and in combination  
B. Serum TxB2 levels were measured in CAD patients on chronic treatment with aspirin 
or aspirin plus clopidogrel   
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4. MATERIALS AND METHODS 
 
4.1 Study population 
Healthy subjects 
Blood samples from 24 apparently healthy male (n=14) and female (n=10) volunteers (range: 20-
63 years of age) were studied. They were recruited among the laboratory personnel and medical 
students of our institution. All subjects abstained from any drug known to affect platelet function 
for at least 10 days before blood sampling were enrolled.  
Patients with P2Y12  deficiency: 
Three patients with bleeding diathesis and defects of P2Y12 were studied: two patients with 
inherited, severe P2Y12 deficiency (one man, aged 77 y and one woman, aged 65 y) 
104
 
105
 and 
one patient with heterozygous P2Y12 deficiency  
105
 
106
 (Table 3) 
 
Table 3. Clinical baseline characteristics of patients with P2Y12 defects 
Patient  1 
104
 2 
105
 3 
105
 
106
 
Congenital defect 
SevereP2Y12 
deficiency 
SevereP2Y12 
deficiency 
Haploinsufficiency of 
P2Y12  
Clinical 
characteristics 
Moderate/severe 
bleeding diathesis  
Moderate/severe 
bleeding diathesis 
No overt bleeding 
diathesis 
Platelet function 
Severely impaired 
responses to ADP  
Severely impaired 
responses to ADP  
Mild abnormalities of 
platelet function 
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PRINA study patients: 
Twenty consecutive patients, aged 23-69 years, were recruited and participated in the PRasugrel IN 
Asthma (PRINA) study after providing written informed consent. Patients with allergic asthma (>1 
year) with mild and stable asthma without chronic medication, except for the use of inhaled low 
dose of steroids or the use of inhaled beta2-agonist on demand disease, non-smoking, were recruited 
at the Pneumology Unit of Ospedale San Paolo. All patients abstained from any drug known to 
affect platelet function for at least 10 days before blood sampling, and throughout the duration of 
the study. 
Patients were randomized in a cross-over study, in double-blind treatment, placebo-controlled. 
Patients were treated with 10 mg prasugrel q.i.d. or placebo for 14 days with a washout ≥ 15 days 
(Figure 7). Compliance was assessed by interview. The study was approved by the ethics committee 
of Ospedale San Paolo, Milan, Italy and all subjects provided informed consent (ClinicalTrials.gov 
Identifier: NCT01305369). 
 
Figure 7. PRINA study design  
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CAD study patients 
In this study 49 stable CAD patients were enrolled from the Cardiology Unit, at Ospedale San 
Paolo, Milan (IT) after providing written informed consent. All patients were on chronic treatment 
(≥4 weeks) with daily dose (100 mg) of enteric coated acetylsalicylic acid (Cardioaspirin, Bayer, 
DE), 25 patients were also on treatment with a daily dose (75 mg) of clopidogrel (Plavix, Sanofi 
Aventis, FR). Patients were eligible for the study if they met all of the following inclusion criteria: 
1) over than 18 years of age, 2) free of warfarin or drugs known to affect platelet function (e.g. non-
steroidal anti-inflammatory drugs, ticlopidine, dipyridamol) in the two weeks before the blood 
sampling, 4) any ischemic event or revascularization procedure not less than 3 months before 5) any 
drug or alcohol abuse.  
To optimize compliance and uniform pharmacokinetics, all subjects were asked to ingest ASA or 
ASA plus clopidogrel at 9:00 AM of the day preceding blood sampling (day -1) and the blood 
samples were taken exactly 24 h after the last dose.  
The study was conducted in agreement with the Helsinki-II declaration and was approved by the 
Ethics Committees of the Ospedale San Paolo (N° 958), Milano, IT. 
 
4.2  Reagents 
Arachidonic acid (AA), epinephrine, ADP and indomethacin were supplied by Sigma Aldrich 
(Milano, IT). Horm collagen from Mascia Brunelli (Milano, IT). Ticagrelor (TIC), Active 
metabolite of Clopidogrel (CAM) and Active metabolite of Prasugrel (PAM) were kindly provided 
by AstraZeneca R&D (Mölndal Sweden). Cangrelor (Cang) was from The Medicines Company. 
All concentrations of reagents reported in the text have been expressed as final concentrations. 
 
4.3 Blood sampling 
Patients had to refrain from smoking for at least 2h before blood sampling; a light breakfast was 
allowed in the morning of the study. Blood samples were collected from an antecubital vein, 
using a 21 gauge butterfly needle and a tourniquet, released soon after needle insertion. The first 
3 mL of blood were collected into K-EDTA and analyzed by coulter hematology analyzer 
(Beckman Coulter, Milano, IT), the following blood was collected in into plastic tubes (PP) 
containing trisodium citrate (109 mM, 1:9, v/v) or Lepirudin 25 ug/mL, 16.000 ATU/mg (Verum 
Diagnostica, Munich, DE), gently mixed, allowed “ to rest” at room temperature for 15 min, and 
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used for platelet aggregation studies. For phosphorylated-VASP assay.3 mL of blood were 
collected into a commercial tube containing trisodium citrate (109 mM, 1:9, v/v). 
 
4.4 Platelet aggregation experiments  
To assess the platelet aggregation light transmission aggregometry (LTA) was used according to 
manufacturer’s instructions by Chrono-Log 560 (Havertown, PA, USA) or by the Platelet 
Aggregation Profiler (model PAP-8E, Biodata, Horsham, PA, USA). Platelet rich plasma (PRP) 
was obtained by centrifugation of citrate or hirudin whole blood samples at 200 x g for 10 min at 
room temperature as recommended  
107
 Autologous platelet-poor plasma (PPP) was obtained by 
further centrifugation at 1.400 x g for 15 min at room temperature. Autologous PPP was used to set 
the instrument’s 100% light transmission, while the un-stimulated PRP was used to set 0% light 
transmission. The individual platelet count of the PRPs was not adjusted to a pre-determined range, 
because this procedure may induce artefacts 
108
. All aggregation tests were performed within 3 
hours after blood collection. PRP was placed  into a test tube containing a stir bar, P2Y12 
antagonists or vehicle were added and pre-incubated at 37°C for 10 min without stirring followed 
by 2 min under stirring (1.000 r.p.m). Subsequently, platelet aggregation was induced by 
arachidonic acid (1 mM), collagen (0,5 or 10 µg/mL), or ADP (10µM) then recorded for 3 min. 
Maximal aggregation response to each agonist was considered and expressed as percentage. 
In the set experiments without stirring, after addition of platelet agonist, the test tubes were placed 
at 37°C under soft stirring, just 100 r.p.m. for 10 seconds to well mix the agonist, then stopped the 
stirring, and recorded for 3 min. 
In some sets of experiments, only cangrelor (10 uM) was used, epinephrine (1µM) was added at the 
same time with the agonists (collagen 0,5 µg/mL or 10 µg/mL) and platelet aggregation was 
performed both in citrate-PRP and hirudin-PRP. 
 
4.5  TXB2 measurements 
Sample preparation 
Serum was prepared from non-anticoagulated venous blood, allowed to clot at 37°C exactly for 1 
hour, centrifuged at 1,400 x g for 15 min at RT, and stored at -80°C until the analysis. 
For the in vitro studies: 10 mL of non-anticoagulated venous blood were collected and divided in 
aliquots of 1 mL. Immediately after, 10 µL of DMSO or P2Y12 inhibitors at different concentrations 
(10 µM and 100 µM) were added to the aliquots and allowed to clot in the conditions previously 
described. 
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Supernatants were obtained by centrifuging PRP at the end of the observation period of aggregation 
induced by AA or collagen. Cyclooxygenase activity was halted by the addition of indomethacin 
(20 µM) at 13.000×g for 1 min at RT and stored at -80°C until the analysis.  
All data are expressed as pmoles/10
8
 plts considering the appropriated platelet count. 
 
Quantification of TXB2 by EIA 
TxA2 has a short half-life under physiological conditions, TxA2 levels are typically monitored by 
measurement of TXB2 produced by non-enzymatic hydration of TxA2. TxB2 levels, were measured 
by using a selective, competitive enzyme immunoassay (Thromboxane B2 EIA kit, Cayman 
Chemical Company, Ann Arbor,MI, USA) in serum and in the supernatants of citrated-hirudin PRP, 
according to the manufacturer’s instructions. Frozen samples were thawed at 37°C and diluted 
between 1:2 and 1:3000 with buffer and tested in duplicated. The plate was read at 405 nm 
wavelength by a standard 96-well plate reader (TecanTM Sunrise). Samples were assayed parallel 
to known TxB2 standards, prepared as outlined in the manufacturer’s instructions, and a maximum 
binding control. The percentage binding of known standards was calculated in reference to the 
maximum binding control wells, plotted against the logarithm of concentration and analyzed by 
non-linear regression. Unknown samples were expressed in a similar fashion, interpolated from this 
standard curve and corrected for dilution. Samples with results outside the standard curve were re-
assayed with appropriate dilution. The detection limit of the assay is 11 pg/mL. Data are expressed 
as pmoles/108 plts based on the platelet count in K-EDTA samples. 
 
4.6 VASP phosphorylation assay 
In order to evaluate the degree on P2Y12 inhibition, in patients of PRINA and CAD study 
commercial VASP assay (Diagnostica Stago, Asnières, Stago, FR) was performed and the degree of 
P2Y12 receptor inhibition was measured as percentage of platelet reactivity index (PRI). 
The phosphorylation of vasodilator-stimulated phosphoprotein (VASP), an intraplatelet actin 
regulatory protein, is dependent on the level of activation of the platelet P2Y12 receptor, which is 
targeted by P2Y12 antagonist. The VASP phosphorilation analysis was performed according to the 
manufacturer’s instructions within 48 hours after blood collection using PLT VASP/P2Y12 kit 
(Diagnostica Stago, Asnières, FR). Briefly, the anticoagulated blood samples were incubated with 
PGE1 alone or in combination with ADP for 10 min at room temperature and fixed with 
paraformaldehyde. The platelets were then permeabilized with non-ionic detergent and labelled 
using a primary monoclonal antibody against 239-phosphorylated VASP (16C2), followed by a 
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secondary fluorescein isothiocynate-conjugated polyclonal goat anti-mouse antibody. The samples 
were analysed by dual colour flow cytometer (FC500, Beckman-Coulter) and the platelet 
population was identiﬁed from its forward and side scatter distribution, 10.000 platelets were gated. 
The analysis allowed to compare the two tested conditions and to evaluate for both samples the 
capacity of ADP to inhibit VASP phosphorilation. The results were expressed as the platelet 
reactivity index (PRI) calculated using corrected mean fluorescence intensities (MFIc), reflecting 
VASP phosphorilation, of samples incubated with PGE1 alone or PGE1 plus ADP according to the 
following calculation: 
  
PRI = [(MFIc PGE1- MFIc (PGE1+ADP)) / MFIc PGE1] X 100 
 
4.7 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism v5 (GraphPad Software Inc, CA, 
USA). Normal distribution was evaluated by D'Agostino-Pearson test. Parametric or non-parametric 
tests were used as appropriated. Paired t-test or Wilcoxon test were employed for comparison 
between two groups. For comparison among multiple groups one-way ANOVA or Friedman test 
were used followed by Dunn’ post hoc test. 
Differences were considered statistically significant with p-value <0.05. Results were expressed as 
median with range. 
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5. RESULTS 
5.1 Population characteristics  
 
Clinical and demographic characteristics of the subjects studied are summarized in table 4. Only 
patients enrolled in CAD study had personal history of one or more of the following: coronary 
stenosis (18%), myocardial infarction (61%), angina (8%), percutaneous coronary intervention 
(59%), coronary artery by-pass grafting (20%), without differences between the group treated with 
aspirin and that treated with aspirin plus clopidogrel.  
 
5.2 Serum TXB2 experiments 
5.2.1. Ex vivo experiments 
Levels of serum TxB2 in healthy subjects and in patients with P2Y12 deficiency  
The levels of serum TxB2 in two patients with congenital severe P2Y12 deficiency and in one patient 
with haploinsufficiency of the P2Y12 gene were comparable to those measured in a group of healthy 
subjects (n=56) (Table 5).  
 
Levels of serum TxB2 in patients on daily treatment with prasugrel (PRINA study) 
Serum TxB2 levels, measured before and after treatment with prasugrel or placebo in the PRINA 
study were not significantly different (figure 8), despite the fact that prasugrel was highly effective 
in inhibiting P2Y12 , as shown by the VASP phosphorylation assay (figure 9).  
5.2.2. In vitro experiments 
Levels of serum TxB2 in the presence and absence of P2Y12 inhibitors added in vitro 
 
As the ex vivo studies showed that the P2Y12 antagonism or deficiency does not affect the serum 
TXB2 production, in order to test whether P2Y12 antagonists have off-target effects on the platelet 
production of TxA2, serum TxB2 levels were determined after the in vitro addition of cangrelor, 
ticagrelor, CAM, and PAM or vehicle at high concentrations. The levels of serum TxB2 in presence 
of P2Y12 antagonists at all tested concentrations were not decreased (Table 5). 
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Table 4.: Population characteristics 
 
 
Healthy Subjects 
(n=24) 
P1 P2 P3 
PRINA patients 
(n=20) 
CAD patients (ASA) 
(n=24) 
CAD patients (ASA + 
CLO) (n=25) 
 
Sex (M/F) 
 
14/10 
 
M 
 
F 
 
M 
 
14/6 
 
20/4 
 
23/2 
Age (Y) 27 (20-63) 77 65 29 44 (23-69) 73 (51-83) 65(45-8) 
WBC (x 10
9
/L) 6.8 (4.0-8.5) 6.9 2.9 4.4 7.2 (4.4-8.7) 6.9 (3.5-10.2) 7.1 (3.1-11.4) 
RBC (x 10
12
/L) 4.5 (3.7-6.0) 4.4 4.1 5.0 4.8 (3.9-7.0) 4.5 (3.8-5.7) 4.6 (3.0-5.5) 
Hb (g/dL) 13.1(9.8-16.3) 13.13 12.4 15.2 14.5 (11.6-17.4) 13.9 (11.8-16.3) 14.0 (9.8 - 16.6) 
Hematocrit (%) 39.7(31.5-50.3) 39.5 37.7 45.8 42.9 (34.8-50.2) 43.0 (37.7-49.7) 42.8 (28.8-50.4) 
Platelets (x 10
9
/L) 207 (143-329) 170 118 139 243 (163-381) 169 (102-314) 190 (136-308) 
MPV, (fL) ND 9.8 10.6 ND 8.3 (6.8-12.1) 9.6 (7.7-12.0) 10.0 (7.0-11.6) 
Medications        
Oral hypoglycemic   
agents 
- - - - - 2/24 10/25 
Statins - - - - - 14/24 25/25 
Diuretics - - - - - 8/24 3/25 
Antiulcer - - - - - 11/24 17/25 
Antihypertensive - - - - - 18/24 23/25 
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Table 5. SerumTxB2 levels in patients with congenital P2Y12 defects and in healthy subjects (n=7), 
in presence/absence of in vitro P2Y12 inhibitors 
 
 
  
*TxB2: 
pmoles/10
8 
plts 
Patient 1: 
homozygous 
P2Y12    
deficiency 
Patient 2: 
homozygous 
P2Y12    
deficiency 
Patient 3: 
heterozygous 
P2Y12  
deficiency 
Healthy 
subjects 
(n=7) 
Normal 
range 
(n=56) 
Vehicle 262,7 158,2 112,1 
181,6 
(96,6 - 488,7) 
64,9 - 482,3 
Cangrelor 
10 µM 325,5 190,6 ND 
189,9 
(112,3 -388,7) 
- 
100 µM 275,8 229,5 ND 
256,4 
(75,5 – 439,0) 
- 
Ticagrelor 
10 µM 252,8 192,4 125,7 
320,5 
(94,4 – 415,7) 
- 
 
100 µM 200,2 166,4 77,4 
221,0 
(84,1 – 292,7) 
- 
Clopidogrel 
active 
metabolite 
10 µM 277,2 196,2 76,3 
222,2 
(103,1 -484,8) 
- 
100 µM 288,3 181,8 75,5 
238,1 
(107,6 -606,9) 
- 
Prasugrel 
active 
metabolite 
10 µM 266,6 171,9 98,2 
180,8 
(89,1 - 362,5) 
- 
100 µM 248,0 154,6 70,6 
177,0 
(146,9-591,1) 
- 
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Figure 8. Serum TxB2 levels in 20 patients with bronchial asthma before and after 14 day treatment with prasugrel (10 
mg q.i.d.) or placebo. The TxB2 levels were determined in duplicate by a commercial EIA. Data are shown as median 
(line in box), 25–75% percentile (box), and 10–90% percentile (whiskers) and were analysed by repeated measures and 
non-parametric statistical test ( Friedman test, p = 0.42 ). 
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Figure 9. Platelet VASP phosphorylation, expressed as Platelet Reactivity Index (PRI), in patients (n=20) with asthma 
15 days after treatment with placebo or prasugrel (10 mg/day). Data are shown as median and were analysed by 
repeated measures and non-parametric statistical test plus Dunn's multiple comparison post-test. 
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5.3 Effects of P2Y12 antagonists on TXB2 production by platelet-rich plasma stimulated by 
agonists in an aggregometer 
Experiments with citrate-anticoagulated platelet-rich plasma from healthy subjects. 
Two different platelet agonists were chosen to test the effect of P2Y12 inhibitors on TXB2 
production and aggregation of platelet-rich plasma in citrate anticoagulant: exogenous arachidonic 
acid, and collagen, which induces TXB2 production from endogenous arachidonic acid. When 
experiments were performed under stirring conditions (which allow platelet aggregation to occur), 
each P2Y12 antagonist (Cangrelor, Ticagrelor, CAM or PAM) caused a statistically significant and 
similar reduction of platelet aggregation and of TxB2 production by platelets that had been 
stimulated by arachidonic acid or collagen (Figure 10).  In contrast, when experiments were 
performed under non-stirring conditions (which prevent the formation of detectable platelet 
aggregates), no platelet aggregation was detected and no differences in TXB2 production were 
observed in presence/absence of P2Y12 antagonists (Figure 10). All tested P2Y12 inhibitors caused 
severe inhibition of platelet aggregation induced by ADP (10 µM) (data not shown). 
 
Experiments with citrate-anticoagulated platelet-rich plasma from patients with inherited severe 
P2Y12 deficiency. 
As expected, the aggregation of P2Y12 deficient platelets in response to arachidonic acid or collagen 
was lower than that of healthy subjects. The in vitro addition of P2Y12 antagonists did not further 
inhibit platelet aggregation (Figure 10). TxB2 production by P2Y12-deficient platelets was 
comparable to that observed by normal platelets in the presence of P2Y12 antagonists, and was not 
further reduced by P2Y12 antagonists added in vitro, both under stirring and non-stirring conditions 
(Figure 10).  
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Figure 10. Platelet aggregation (measured by LTA) and TxB2 production in citrate PRP of healthy subjects (n=13) 
(upper graphs) and two patients with inherited, severe P2Y12 deficiency (lower graphs), after stimulation with 
arachidonic acid (1 mM) or collagen (0,5 µg/mL). Each antagonist (10µM) or vehicle was added to PRP and pre-
incubated at 37°C without stirring for 10 min, followed by 2 min pre-incubation with stirring. Once mixed, PRP was 
stimulated with agonist under two different conditions: with stirring and with no stirring. Platelet aggregation was 
monitored for 3 min, after which samples were centrifuged and the supernatant platelet-poor plasma and the supernatant 
platelet-poor plasma was separated and stored at -80 °C until assay of TxB2 levels by EIA (see Materials and Methods 
for details). The data are shown as medians (line in box), 25–75% percentiles (box), and 10–90% percentiles (whiskers). 
Data were analysed by Friedman for repeated measures using a non-parametric statistical test plus Dunn's multiple 
comparison post-test. 
Arachidonic acid 1 mM 
P
2
Y
1
2
 d
e
f.
 p
a
ti
e
n
ts
  
  
H
e
a
lt
h
y
 s
u
b
je
c
ts
 
L
ig
h
t 
tr
a
n
s
m
is
s
io
n
 (
%
) 
0
20
40
60
80
100
p< 0.0001 (Friedman)
DMSO Cang Tic CAM PAM
0
20
40
60
80
100
Stirring (1,000 rpm) 
 T
x
B
2
 (
p
m
o
le
s
/1
0
8
p
lt
s
) 
DMSO Cang Tic CAM PAMDMSO Cang Tic CAM PAM
0
500
1000
1500
2000
0
500
1000
1500
2000
p=0.0002  (Friedman) p=ns (Friedman)
Stirring (1,000 rpm) No stirring 
Collagen 0,5 µg/mL 
P
2
Y
1
2
 d
e
f.
 p
a
ti
e
n
ts
  
  
H
e
a
lt
h
y
 s
u
b
je
c
ts
 
L
ig
h
t 
tr
a
n
s
m
is
s
io
n
 (
%
) 
Stirring (1,000 rpm) 
0
20
40
60
80
100
 p< 0.0001 (Friedman)
DMSO Cang Tic CAM PAM
0
20
40
60
80
100
 T
x
B
2
 (
p
m
o
le
s
/1
0
8
p
lt
s
) 
DMSO Cang Tic CAM PAM
0
25
50
75
100
125
150
DMSO Cang Tic CAM PAM
0
25
50
75
100
125
150
p<0.0001 (Friedman) p=ns (Friedman)
Stirring (1,000 rpm) No stirring 
  
 
39 
 
5.4 Further evidence that the inhibitory effect of P2Y12 antagonists on TxB2 production by 
platelets is mediated by the inhibition of platelet aggregation. 
In order to test further the hypothesis that the described inhibitory effect of P2Y12 antagonists on 
TxB2 production by platelets is secondary to the inhibition of platelet aggregation, we performed 
additional studies, under different experimental conditions. 
5.4.1 Effects of hirudin anticoagulant and of epinephrine 
As the aggregation-dependent platelet production of TxB2 is greatly enhanced under conditions of 
low plasma [Ca2+], we compared the effects of cangrelor on collagen-induced platelet aggregation 
in citrate-PRP (low [Ca2+]) and hirudin-PRP (physiological [Ca2+]).  The extent of both platelet 
aggregation and TxB2 production induced by collagen was greater in citrate-PRP than in hirudin-
PRP (Table 6) Cangrelor dramatically inhibited platelet aggregation and TxB2 production both in 
citrate-PRP and hirudin-PRP. The addition of epinephrine, which, like ADP/ P2Y12 stimulates an 
inhibitory G-protein through its interaction with its receptor, restored platelet aggregation and TxB2 
production in the presence of cangrelor both in citrate-PRP and hirudin-PRP. 
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Table 6. Effect of epinephrine on platelet aggregation and TxB2 production induced by collagen (0.5 µg/ml) in 
citrate-PRP and hirudin-PRP from healthy subjects 
 
Collagen  0,5 
( µg/mL ) 
Vehicle 
(n=6) 
Cangrelor 
(n=6) 
Cangrelor + 
epinephrine 
(n=6) 
Citrate-PRP    
Platelet aggregation 
(percent) 
63 
(8-70) 
11 
(0-37) 
59 
(19-70) 
TxB2 (pmoles/108 plts) 33.6 
(12.3-75.3) 
11.8 
(7.91-22.8) 
20.4 
(8.8-51.1) 
Hirudin-PRP    
Platelet aggregation 
(percent) 
45 
(1-99) 
1 
(0-3) 
44 
(7-100) 
TxB2 (pmoles/108 plts) 6.9 
(4.1-19.1) 
3.9 
(2.1-8.8) 
6.6 
(2.8-15.1) 
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5.4.2 Effects of MRS2500, an inhibitor of the platelet P2Y1 receptor for ADP 
The addition of MRS2500 (an inhibitor of P2Y1, the other ADP receptor on platelets) to citrate-
PRP had effects on collagen-induced platelet responses that were similar to those observed after the 
addition of P2Y12 antagonists: platelet aggregation and TxB2 production were significantly 
inhibited under stirring conditions, while no inhibitory effects on TxB2 production were observed 
under non-stirring conditions (Figure 11).  
 
 
 
 
 
 
 
Figure 11. In vitro effects of MRS2500, an inhibitor of the P2Y1 platelet receptor for ADP, on platelet aggregation and 
TxB2 production induced by collagen 0.5 µg/mL in citrate PRP of healthy subjects (n= 6). MRS2500 or vehicle was 
added to PRP and pre-incubated at 37°C without stirring for 10 min, followed by 2 min pre-incubation with stirring. 
Once mixed, PRP was stimulated with agonist under two different conditions: with stirring and with no stirring. Platelet 
aggregation was monitored for 3 min, after which samples were centrifuged and the supernatant platelet-poor plasma 
and the supernatant platelet-poor plasma was separated and stored at -80 °C until assay of TxB2 levels by EIA (see 
Materials and Methods for details). The data are shown as medians (line in box), 25–75% percentiles (box), and 10–
90% percentiles (whiskers). Data were analyzed by Friedman for repeated measures using a non-parametric test plus 
Dunn's multiple comparison post-test.  
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5.5 Comparison of the inhibitory effects of aspirin and cangrelor, alone and in combination, 
on platelet aggregation and TxB2 production  
Experiments were performed using citrate-PRP and hirudin-PRP, both low (0.5 ug/ml) and high (10 
ug/ml) concentrations of collagen  
5.5.1 Collagen 0.5 ug/ml 
Aspirin and cangrelor inhibited platelet aggregation and TxB2 production induced by collagen 0.5 
ug/ml (Figure 12). With the exception of platelet aggregation in hirudin-PRP, in which the 2 
inhibitors had a similar effect, aspirin proved to be a better inhibitor than cangrelor. The 
combination of aspirin and cangrelor did not significantly inhibit collagen-induced platelet 
aggregation and TxB2 production further, compared to aspirin alone (figure 12). 
 
 
 
 
 
 
 
 
 
 
Figure 12. Effects of cangrelor and aspirin, alone and in combination, on platelet aggregation and TxB2 production 
induced by collagen 0.5 µg/mL in citrate or hirudin PRP. Each compound or vehicle was added to PRP and pre-
incubated at 37°C without stirring for 10 min, followed by 2 min pre-incubation with stirring. Once mixed, PRP was 
stimulated with agonist under two different conditions: with stirring and with no stirring. Platelet aggregation was 
monitored for 3 min, after which samples were centrifuged and the supernatant platelet-poor plasma was separated and 
stored at -80 °C until assay of TxB2 levels by EIA (see Materials and Methods for details). The data are shown as 
medians (line in box), 25–75% percentiles (box), and 10–90% percentiles (whiskers). Data were analyzed by Friedman 
for repeated measures using a non-parametric test plus Dunn's multiple comparison post-test.  
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4.5.2. Collagen 10 ug/ml  
Aspirin and cangrelor only partially inhibited platelet aggregation induced by collagen 10 ug/ml 
both in citrate-PRP and hirudin-PRP: no statistically significant differences were observed in the 
degree of inhibition by the 2 drugs, when they were added alone. The combination of aspirin and 
cangrelor dramatically reduced the extent of platelet aggregation. Both cangrelor and aspirin 
significantly inhibited TxB2 production both in citrate-PRP and hirudin-PRP, but aspirin proved to 
be more effective. The combination of aspirin and cangrelor completely abolished TxB2 production 
(figure 13). 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Effects of cangrelor and aspirin, alone and in combination, on platelet aggregation and TxB2 production 
induced by collagen 10 µg/mL in citrate or hirudin PRP. Each compound or vehicle was added to PRP and pre-
incubated at 37°C without stirring for 10 min, followed by 2 min pre-incubation with stirring. Once mixed, PRP was 
stimulated with agonist under two different conditions: with stirring and with no stirring. Platelet aggregation was 
monitored for 3 min, after which samples were centrifuged and the supernatant platelet-poor plasma was separated and 
stored at -80 °C until assay of TxB2 levels by EIA (see Materials and Methods for details). The data are shown as 
medians (line in box), 25–75% percentiles (box), and 10–90% percentiles (whiskers). Data were analyzed by Friedman 
for repeated measures using a non-parametric test plus Dunn's multiple comparison post-test. 
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5.6. Serum TXB2 levels in CAD patients on chronic treatment with aspirin or aspirin plus 
clopidogrel 
 
Levels of serum TXB2 were very low in CAD patients treated with aspirin or aspirin plus 
clopidogrel both 3h and 24h after the last drug intake. There was no statistically significant 
difference in the serum TxB2 levels in patients treated with aspirin alone compare to patients 
treated with aspirin plus clopidogrel both at 3h and 24h after the last drug intake (Figure 14).  
 
 
 
Figure 14. Serum TxB2 levels of 24 patients on chronic daily treatment with aspirin (100 mg) and 25 patients on 
chronic daily treatment with aspirin (100 mg) plus clopidogrel (75 mg). TxB2 levels were assayed in duplicate using a 
commercial EIA (see Materials and Methodsa for details). Data are shown as medians (line in box), 25–75% percentiles 
(box), and 10–90% percentiles (whiskers), and were analyzed the Mann Whitney test (p= ns). 
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6. DISCUSSION AND CONCLUSIONS 
Current management of ACS patients targets primary drivers of platelet aggregation: TxA2 and 
ADP by a combination therapy of aspirin and a P2Y12 antagonist. Based on the recent 
observation 
101
 
102
 
109
 that P2Y12 antagonists also inhibit the platelet production of TxA2, it has 
been suggested that patients with ACS might be safely treated with P2Y12 antagonists only 
110
. In 
contrast, our previous observations demonstrated that P2Y12 deficiency did not lead to a 
reduction of serum TxB2 
104
 
105
. 
Given the need to provide novel insight into the controversial issue about the effect of P2Y12 
receptor antagonism on TxA2 generation, in this study we tested the hypotheses that the reported 
inhibitory effect of P2Y12 antagonists on TxA2 production may be: 1) due to off-target effects, 
(addressed by the in vitro, ex vivo effect of P2Y12 antagonists) 2) secondary to the inhibition of 
platelet aggregation (addressed by the in vitro addition of P2Y12 antagonists in presence or 
absence of aggregation). 
The major conclusion of the present study is that the reported reduction of TxA2 production after 
the addition of P2Y12 antagonist is not due to unspecific effects of the compounds as they do not 
affect serum TxA2 levels both in vitro and ex vivo, but only secondary to the inhibition of 
platelet aggregation.  
In addition, we also demonstrated that P2Y12 antagonist is not able to reduce TXB2 in a comparable 
extent as aspirin, and even the combination of both does not add any benefit in terms of  reduction 
of TxB2 production neither in in vitro nor in ex vivo experiments.  
Firstly, we confirmed that serum TxA2 of 3 patients with congenital P2Y12 defects, either 
haploinsufficiency or severe  deficiency, were in the normal range.  
However, these data did not exclude that administration of P2Y12 antagonists may affect TxB2 
production as suggested by Bhavaraju  et al 
101
. Our hypothesis is based on recent findings that 
support the idea that irreversible P2Y12 antagonists (tienopyridines) have off-target activity 
affecting the bleeding, not entirely P2Y12 dependent 
111
. 
 Focusing on the off-target activity of P2Y12 antagonists (cangrelor, ticagrelor, PAM and CAM) we 
observed that their in vitro addition during the serum preparation did not modify the TxB2 levels in 
healthy subjects compared to the vehicle. All compounds were added at two different 
concentrations both in excess respect to the effective peak plasma concentration to secured 
complete pharmacological inhibition of P2Y12 receptor. These results were similar to those found in 
patients with congenital P2Y12 deficiency and were quite consistent across them.  
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Consistent with these in vitro data, results of PRINA trial reported that subjects receiving prasugrel 
had normal serum TxB2 levels and not significantly reduced compared to the placebo. Prasugrel 
was chosen because it is a third-generation thienopyridine, with faster onset of action and a more 
uniform inhibition of platelet function compared to clopidogrel. Indeed, in our study population we 
found a very low residual platelet reactivity (median PRI 26%, 0-55).  Hence, this controlled, 
randomized study provides proof-of-concept that pharmacological inhibition of the platelet P2Y12 
receptors does not affect serum TxB2 production neither directly nor by unspecific effects due to in 
vivo formed metabolites. 
Taken together, this findings are not in agreement with Bhavaraju et al and Kidson-Gerber et al. 
studies 
101
 
109
.  We do not have an explanation for this discrepancy, but in our experience, the 
assessment of TxB2 production has high inter-intra individual variability over time as the tables 2 
and figure 1 show. 
With this in mind, we controlled the variability, indeed the design of the pilot study virtually 
excluded the possibility that any difference was due to the variability between individuals and 
the in vitro experiments were performed starting from the same blood sample. 
In addition, it is important to note that serum TxB2 levels found here are quite different from 
those reported by Bhavaraju et al and Kidson-Gerber et al., although our reference range, 
obtained from a large number of healthy subjects, was consistent with those reported by others  
112
 table 2 
Hence, our study provides multiple consistent lines of evidence that neither deficiency nor 
blockade of  P2Y12 receptor do lead to the reduction of TxB2 generation under thrombin 
stimulus.   
However, the results reported here are in contrast with some studies which showed that ADP- 
directly induced TxB2 generation in human platelets 
100
 and that P2Y12 inhibitors are able to 
reduce in vitro platelet aggregation and TxA2 production induced by several agonists 
103
 
113
 
114
 
102
. 
Thus, we conducted in vitro experiments on citrated-PRP to provide novel insight in the 
understanding if the reduction of TxB2 due to P2Y12 antagonists is only secondary to the 
inhibition of platelet aggregation. 
As expected, we found that P2Y12 antagonists caused a reduction of platelet aggregation and a 
consequent reduction of TxA2 synthesis when agonists such as AA and collagen, able to directly 
stimulate TxA2 synthesis, were employed. 
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However, these experiments simultaneously repeated under non-stirring conditions, when 
platelet aggregation does not occur, showed no reduction of TxB2 production in presence of 
P2Y12 antagonists. 
The same pattern of results was found in both groups, healthy subjects and in 2 patients with 
severe, congenital P2Y12 deficiency. In both cases, P2Y12 receptor resulted strongly inhibited as 
demonstrated by ADP-induced platelet aggregation. 
Our data suggest that synthesis of endogenous TxA2 is triggered by the close platelet-to-platelet 
contact that occurs during platelet aggregation, in agreement with the well-established 
knowledge that the ADP via P2Y12 receptor can induce directly platelet aggregation, but not 
TxA2 production 
115
 
116
.  
Indeed platelet-to platelet contacts caused by weak agonists, such as ADP, causes the formation 
of trace amounts of TxA2 and consequent secretion of ADP. When platelets aggregate and reach 
a threshold level trigger TxA2 generation, which causes platelet secretion and, in collaboration 
with secreted ADP, a second and irreversible wave of aggregation by interacting with its 
receptor P2Y12.  
In agreement with this, the stimulation of Giα family member Gzα by a weak agonist as 
epinephrine is able to completely reverse the cangrelor inhibition of collagen induced platelet, 
but is not able to reverse TxB2 production completely, confirming that weak agonist is not able 
to directly induce TxB2 production.   
The results of this study provide novel insight in the understanding the effect of ADP/ P2Y12 
receptor pathway on the TxA2 production that may have a clinical relevance because is still 
argue the better medication strategy to prevent blood from clotting and, at the same time, to 
minimize the complications due to the therapy after a stent procedure.  
The main contribution in this field will come from the results of GLOBAL LEADER trial (NCT 
01813435) currently ongoing. This study will evaluate “Comparative Effectiveness of 1 Month 
of Ticagrelor Plus Aspirin Followed by Ticagrelor Monotherapy Versus a Current-day Intensive 
Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary 
Intervention With Drug-eluting Stent Use”. In agreement with some recent studies 113 103, the 
rationale of this trial is based on the hypothesis that aspirin may be not required for long-term 
secondary prevention of recurrent ischemic events. 
However, this hypothesis does not fit with the findings presented here, therefore we also 
investigated whether strong P2Y12 receptor antagonism leads to additional antiaggregatory effect 
to aspirin by comparing, in vitro and ex vivo, individual and combined effects of them. Our data 
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suggest that aspirin provides an additional antiaggregatory effect to a P2Y12 inhibitor (cangrelor) 
owing to a reduction in the aggregation driven- TxA2 formation (collagen 0.5 µg/mL). This 
effect is also more appreciable when the aggregation is not TxA2 dependent (collagen 10 
µg/mL). These observations indicate, just in vitro, that the combination of aspirin and a 
P2Y12antagonist leads to a greater benefit in terms of inhibition of platelet activation compared 
to that produced by strong P2Y12 blockade alone.   
However, we were aware that the effect found here may be affected by the anticoagulant used. 
As it is known, the low extracellular calcium is able to overemphasize the in vitro role and 
production of TxB2 as it happens with citrate anticoagulant. However, it was not our case, 
because our results show the same pattern when the experiments were conducted either in 
citrated PRP and at physiological concentration of calcium by using hirudin.  
Consistent with all results reported here, we also observed in a pilot study, that the chronic 
administration of clopidogrel has no additional effect on serum TxB2 production in CAD 
patients receiving aspirin compared to patients in treatment with aspirin only. That was 
consistent in patients either responders or non-responders to clopidogrel (as indicated by their 
PRI VASP assay, no correlation was found between the PRI and serum TXB2, data not shown). 
In conclusion, our study demonstrates that neither the antagonism nor the antagonists of P2Y12 
receptor are able to directly reduce TxA2 generation in vitro as well as ex vivo and that P2Y12  
receptor is crucial for TxA2 generation only as a secondary player. Consistent with these 
findings, to date, there is no clinical, nor pharmacological/ physiological evidence that aspirin 
should be withheld in patients with acute coronary syndromes, who are generally treated with 
aspirin plus P2Y12 antagonists. 
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